Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2017

23.02.2016 | Case Report

Recurrence of a pT2N0cM0 Lower Third Gastric Cancer with No. 6 Lymph Node Micrometastasis after R0 Extended Surgery. Should Adjuvant Therapy be Performed in Conventionally Node-Negative but Micrometastasis-Positive pT2 Gastric Cancer?

verfasst von: Konstantinos Blouhos, Konstantinos A. Boulas, Konstantinos Tsalis, Nikolaos Barettas, Michail Aftzoglou, Anestis Hatzigeorgiadis

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

D2 lymphadenectomy has been established as the standard procedure for the prevention of lymph node recurrence in resectable stage IB–III gastric cancer. Nevertheless, R0 resection after optimal D2 dissection did not always prevent disease recurrence; one of the key causative factors is lymph node micrometastasis [1]. The seventh TNM classification of malignant tumors clearly stated that micrometastases in regional and distant lymph nodes detected by morphological techniques (serial sectioning combined with H-E staining and immunohistochemistry) should be reported and calculated in the staging of the disease (pN1mi and pM1 LYM+). However, no definitive criteria for examination of lymph nodes micrometastasis were provided [2]. Furthermore, the seventh edition of TNM classification for gastric cancer and the third Japanese classification of gastric carcinoma did not incorporate lymph node micrometastasis in pN categorization and staging [3, 4]. …
Literatur
1.
Zurück zum Zitat Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, et al. Surgical management of advanced gastric cancer: an evolving issue. Eur J Surg Oncol. 2016;42:18–27.CrossRefPubMed Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, et al. Surgical management of advanced gastric cancer: an evolving issue. Eur J Surg Oncol. 2016;42:18–27.CrossRefPubMed
2.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C. International union against cancer (IUCC) TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2010. Sobin LH, Gospodarowicz MK, Wittekind C. International union against cancer (IUCC) TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2010.
3.
Zurück zum Zitat Jung H, Lee HH, Song KY, Jeon HM, Park CH. Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer. 2011;117:2371–8.CrossRefPubMed Jung H, Lee HH, Song KY, Jeon HM, Park CH. Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer. 2011;117:2371–8.CrossRefPubMed
4.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
5.
Zurück zum Zitat Arigami T, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, et al. Clinical significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2013;20:515–21.CrossRefPubMed Arigami T, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, et al. Clinical significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2013;20:515–21.CrossRefPubMed
6.
Zurück zum Zitat Griniatsos J, Michail O, Dimitriou N, Karavokyros I. Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: their clinical significance. World J Gastrointest Oncol. 2012;4:16–21.CrossRefPubMedPubMedCentral Griniatsos J, Michail O, Dimitriou N, Karavokyros I. Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: their clinical significance. World J Gastrointest Oncol. 2012;4:16–21.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40:584–91.CrossRefPubMed Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40:584–91.CrossRefPubMed
8.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef
9.
Zurück zum Zitat Blouhos K, Boulas KA, Hatzigeorgiadis A. Bursectomy in gastric cancer surgery: surgical technique and operative safety. Updates Surg. 2013;65:95–101.CrossRefPubMed Blouhos K, Boulas KA, Hatzigeorgiadis A. Bursectomy in gastric cancer surgery: surgical technique and operative safety. Updates Surg. 2013;65:95–101.CrossRefPubMed
10.
Zurück zum Zitat Blouhos K, Boulas KA, Tsalis K, Hatzigeorgiadis A. Right-sided bursectomy as an access plane for aesthetic resection of the posterior leaf of the lesser sac from the head of the pancreas en-block with the No. 6 and 14v lymph nodes in advanced lower-third gastric cancer. Surgery. 2015;158:1742.CrossRefPubMed Blouhos K, Boulas KA, Tsalis K, Hatzigeorgiadis A. Right-sided bursectomy as an access plane for aesthetic resection of the posterior leaf of the lesser sac from the head of the pancreas en-block with the No. 6 and 14v lymph nodes in advanced lower-third gastric cancer. Surgery. 2015;158:1742.CrossRefPubMed
11.
Zurück zum Zitat Sobin LH, Wittekind C. International Union against Cancer. TNM classification of malignant tumours (6th ed). New York: Wiley-Liss; 2002. Sobin LH, Wittekind C. International Union against Cancer. TNM classification of malignant tumours (6th ed). New York: Wiley-Liss; 2002.
12.
Zurück zum Zitat Yasuda K, Adachi Y, Shiraishi N, Inomata M, Takeuchi H, Kitano S. Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol. 2002;9:771–4.CrossRefPubMed Yasuda K, Adachi Y, Shiraishi N, Inomata M, Takeuchi H, Kitano S. Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol. 2002;9:771–4.CrossRefPubMed
13.
Zurück zum Zitat Jeuck TL, Wittekind C. Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases. Gastric Cancer. 2015;18:100–8.CrossRefPubMed Jeuck TL, Wittekind C. Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases. Gastric Cancer. 2015;18:100–8.CrossRefPubMed
14.
Zurück zum Zitat Nakajo A, Natsugoe S, Ishigami S, Matsumoto M, Nakashima S, Hokita S, et al. Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer. Ann Surg Oncol. 2001;8:158–62.CrossRefPubMed Nakajo A, Natsugoe S, Ishigami S, Matsumoto M, Nakashima S, Hokita S, et al. Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer. Ann Surg Oncol. 2001;8:158–62.CrossRefPubMed
15.
Zurück zum Zitat Li Y, Du P, Zhou Y, Cheng Q, Chen D, Wang D, et al. Lymph node micrometastases is a poor prognostic factor for patients in pN0 gastric cancer: a meta-analysis of observational studies. J Surg Res. 2014;191:413–22.CrossRefPubMed Li Y, Du P, Zhou Y, Cheng Q, Chen D, Wang D, et al. Lymph node micrometastases is a poor prognostic factor for patients in pN0 gastric cancer: a meta-analysis of observational studies. J Surg Res. 2014;191:413–22.CrossRefPubMed
16.
Zurück zum Zitat Lee CM, Cho JM, Jang YJ, Park SS, Park SH, Kim SJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer?: the significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2015;22:765–71.CrossRefPubMed Lee CM, Cho JM, Jang YJ, Park SS, Park SH, Kim SJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer?: the significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2015;22:765–71.CrossRefPubMed
17.
Zurück zum Zitat Kim JH, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer. J Surg Res. 2010;162:177–83.CrossRefPubMed Kim JH, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer. J Surg Res. 2010;162:177–83.CrossRefPubMed
18.
Zurück zum Zitat Zeng YJ, Zhang CD, Dai DQ. Impact of lymph node micrometastasis on gastric carcinoma prognosis: a meta-analysis. World J Gastroenterol. 2015;2:1628–35.CrossRef Zeng YJ, Zhang CD, Dai DQ. Impact of lymph node micrometastasis on gastric carcinoma prognosis: a meta-analysis. World J Gastroenterol. 2015;2:1628–35.CrossRef
19.
Zurück zum Zitat Wu ZY, Li JH, Zhan WH, He YL, Wan J. Effect of lymph node micrometastases on prognosis of gastric carcinoma. World J Gastroenterol. 2007;13:4122–5.CrossRefPubMedPubMedCentral Wu ZY, Li JH, Zhan WH, He YL, Wan J. Effect of lymph node micrometastases on prognosis of gastric carcinoma. World J Gastroenterol. 2007;13:4122–5.CrossRefPubMedPubMedCentral
Metadaten
Titel
Recurrence of a pT2N0cM0 Lower Third Gastric Cancer with No. 6 Lymph Node Micrometastasis after R0 Extended Surgery. Should Adjuvant Therapy be Performed in Conventionally Node-Negative but Micrometastasis-Positive pT2 Gastric Cancer?
verfasst von
Konstantinos Blouhos
Konstantinos A. Boulas
Konstantinos Tsalis
Nikolaos Barettas
Michail Aftzoglou
Anestis Hatzigeorgiadis
Publikationsdatum
23.02.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9811-y

Weitere Artikel der Ausgabe 1/2017

Journal of Gastrointestinal Cancer 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.